Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment
Objective: To assess a potential threshold for remission of tardive dyskinesia (TD) during treatment with once-daily valbenazine, a uniquely selective vesicular monoamine transporter 2 inhibitor.…Real-World Effectiveness of the 4-Week Patient Deutetrabenazine-Titration Kit for Tardive Dyskinesia Across Races: START Study Post Hoc Analysis
Objective: To assess the effectiveness of a 4-week deutetrabenazine (DTBZ) titration kit in patients with tardive dyskinesia (TD), stratified by race. Background: The START study…Valbenazine Improves the Burden and Symptoms of Tardive Dyskinesia: Topline Results from the Phase 4 KINECT-PRO Study
Objective: To evaluate the effects of once-daily valbenazine (VBZ) on the impacts of tardive dyskinesia (TD) using multiple patient-reported outcomes (PROs), including the psychometrically validated…Hemichorea and Oromandibular Stereotypies Following Immunomodulatory Therapy in Multiple Myeloma: A Case Report
Objective: To describe a unique case of hemichorea and oromandibular stereotypies as a possible side effect of immunotherapy for multiple myeloma. Background: Multiple myeloma is…Scopolamine-induced Tardive Dyskinesia: A Case Report
Objective: To present a case of scopolamine-related Tardive Dyskinesia (TD) and review the documented anticholinergic-associated cases of TD and the underlying pathophysiology responsible for TD.…Bridging the Care Gap for Individuals with Drug-Induced Movement Disorders Using Telemedicine: A Randomized Pilot Study
Objective: Our goal was to evaluate the feasibility, effectiveness, and acceptability of a remote consultation with a movement disorder neurologist to patients suspected to have…Physical, Mental, and Socioemotional Functional Improvement Following Valbenazine Treatment for TD: a Case Series
Objective: Describe clinical characteristics and changes in mental, socioemotional, and physical domains of individuals with tardive dyskinesia (TD) after valbenazine (VBZ) treatment. Background: Prior research…Exploring the Neuroprotective Potential of Raloxifene and Fulvestrant Against Haloperidol Induced Parkinson Disease; Insights into GPR30/PI3k/Akt/Nrf2 Signaling Pathways
Objective: To investigate the neuroprotective effect of raloxifene and fulvestrant on behavioral, biochemical, neurochemical, and molecular alterations in a haloperidol-induced animal model of Tardive dyskinesia.To…Patient and Caregiver Experiences with Tardive Dyskinesia: Emotions, Challenges, and Unmet Needs in the Patient Journey
Objective: To describe the emotional journey from symptom onset to current state and identify challenges and unmet needs of participants living with tardive dyskinesia (TD)…Effectiveness of Deutetrabenazine for Tardive Dyskinesia When Initiated Using a 4-Week Patient Titration Kit: Final Results of the START Study
Objective: To evaluate the effectiveness, dosing patterns, and patient treatment satisfaction in patients with tardive dyskinesia treated with deutetrabenazine using a 4-week titration kit. Background:…
- 1
- 2
- 3
- …
- 9
- Next Page »